Dyslipidemia

MAR001 significantly lowers remnant cholesterol and triglycerides in Phase 2a data, offering hope for high-risk cardiovascular patients.

NewAmsterdam Pharma announces promising Phase 3 results for obicetrapib, showing significant LDL-C reduction in patients with ASCVD and/or HeFH.

FDA further postpones action date for elamipretide, a potential treatment for Barth syndrome, as discussions on labeling progress.

Data suggest that etripamil may be more effective than vagal maneuvers and oral prophylaxis, minimizing emergency department visits.

A major factor of type 2 diabetes mellitus, dyslipidemia can potentially be prevented by closely monitoring lipid profiles.

Simple choices like improving diet and increasing exercise can influence a healthy individual’s risk of developing cardiovascular disease.

Researchers indicated an association between the index and 365-day mortality.

Christie M. Ballantyne, MD, discusses the role of plozasiran in managing elevated triglycerides and reducing pancreatitis risk.

Bhatt discusses his expectations for the future of cardiology in 2025, including GLP-1-RAs and the push towards combination therapy.

A single infusion of VERVE-102 gene editing therapy achieved dose-dependent lowering in blood PCSK9 and LDL-C in initial results from the Heart-2 trial.

Payal Kohli, MD, explores how evolving tools and strategies in lipid management are reshaping preventive cardiology.

Ruff discusses his expectations for cardiology for the rest of 2025, including new research into GLP-1 receptor agonists.

VERVE-102 is targeting the reduction of LDL-C levels among individuals with hyperlipidemia and high lifetime cardiovascular risk.

Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.

Our Q1 2025 recap for cardiology spotlights 6 regulatory updates, 5 key trial announcements, and top expert perspectives in cardiac care.

A recap of 10 clinical trials in cardiovascular care to know from the American College of Cardiology 2025 Scientific Sessions.

At ACC.25, Boer highlights treatment gaps in the US for lipid control in a high-risk ASCVD population.

At ACC.25, Robert S. Rosenson, MD, discusses the efficacy and safety of solbinsiran, an ANGPTL3 inhibitor, in a population with mixed dyslipidemia.

Steve Nissen, MD, discusses the phase 2 ALPACA trial and how it informs the potential of lepodisiran for lowering Lp(a).

Phase 2 data at ACC.25 provide further insight into the effects of lepodisiran on serum Lp(a) and other biomarkers of risk.

OAC-naive patients experienced a significantly smaller increase in stroke or systemic embolism with asundexian than apixaban.

First Procedure Performed at AHN Wexford Hospital, Demonstrating Network’s Ongoing Commitment to Bringing Complex Cardiovascular Care into the Community

The IND submission for VERVE-102 was supported by interim data from the dose-escalation portion of the ongoing Heart-2 Phase 1b clinical trial.

The approval expands the indication for vutrisiran, which becomes the first therapeutic approved by the FDA for the treatment of ATTR-CM.

Initiation of the MOMENTUM clinical trial will explore the prevalence of endogenous hypercortisolism in patients with resistant hypertension.